Aptose Biosciences Receives New Analyst Coverage

Analysts at StockNews.com have started covering shares of Aptose Biosciences (NASDAQ:APTO). They released their report on Tuesday, setting a "hold" rating for the biotechnology company's stock.

In a separate note, HC Wainwright reaffirmed their "buy" rating for Aptose Biosciences, giving the stock a price target of $2.00 in a research report published on Tuesday, December 10th.

Recent Stock Performance

On Tuesday, Aptose Biosciences saw its stock open at $0.24. The company has a market capitalization of $14.21 million and a price-to-earnings (P/E) ratio of -0.08, with a beta of 1.06. Over the last year, the stock reached a low of $0.13 and a high of $2.60. Current moving averages show a 50-day average price of $0.28 and a 200-day average price of $0.44.

Institutional Investment Trends

Recently, Sigma Planning Corp, a hedge fund, increased its stake in Aptose Biosciences. According to their latest SEC filing, they raised their position by 71.3% during the third quarter, now holding 401,750 shares after acquiring an additional 167,282 shares. As of the most recent reporting period, Sigma Planning Corp owns 2.22% of the company, valued at $165,000. Overall, institutional investors control approximately 26.62% of Aptose Biosciences’ shares.

About Aptose Biosciences

Aptose Biosciences Inc. is a clinical-stage biotechnology firm focused on developing personalized therapies aimed at meeting unmet medical needs in oncology. The company's lead clinical program, APTO-253, is currently in a Phase I clinical trial targeting patients with relapsed or refractory hematologic malignancies.

Additional Information

Investors interested in Aptose should keep an eye on further analyst ratings and market movements. The company remains a significant player in its niche of biotechnology, addressing critical gaps in cancer treatment.

Aptose, Biotechnology, Analysts